Seattle, WA Clinical Trials Report — June 2026

For patients and healthy volunteers in Seattle, WA, June 2026 presents a dynamic landscape of clinical research opportunities. With 1,258 clinical trials currently recruiting across 348 research facilities in the city, there are numerous ways to contribute to medical advancements. This month, a significant number of trials are nearing their enrollment deadlines, creating urgent opportunities for those ready to participate.

Act Now: Trials Closing Soon in Seattle

Individuals considering clinical trial participation should note that 63 trials in Seattle are slated to close within the next 90 days. Among these, 12 trials are still actively seeking healthy volunteers, offering a valuable chance to contribute to research without a specific medical condition. Acting quickly is essential to secure a spot in these time-sensitive studies.

Patients with certain health conditions also have limited time to enroll in trials. Conditions with studies nearing their closing dates include:

• Refractory hematologic malignancy (2 trials)
• Leukemia (2 trials)
• Myeloid leukemia (2 trials)
• Prostate cancer (2 trials)
• Metastatic malignant solid neoplasm (2 trials)
• Acute myeloid leukemia (2 trials)
• HIV infections (2 trials)
• Advanced melanoma (1 trial)
• Advanced malignant neoplasm (1 trial)
• Acute liver injury (1 trial)

New Research Opportunities Emerge in Seattle

Seattle's research community saw a notable increase in new studies this month, with 22 new trials opening in June 2026, compared to 14 in May. This expansion brings fresh avenues for participation across various health areas. The most frequently studied conditions in these new trials include:

• Overweight (2 trials)
• Obesity (2 trials)
• Multiple sclerosis (2 trials)
• Acute myeloid leukemia (2 trials)
• Blood pressure management (1 trial)
• Bone marrow failure (1 trial)
• Autoimmune cytopenia (1 trial)
• Caregiver burden (1 trial)
• Becker muscular dystrophy (1 trial)
• Caregivers (1 trial)

Drug trials lead the way among new study types, with 8 new drug trials, followed by 6 procedure trials, and 5 other types of studies. Academic institutions, particularly the University of Washington and Fred Hutchinson Cancer Center, are sponsoring the majority of these new studies, alongside industry leaders like Kallyope Inc., Novo Nordisk A/S, and AstraZeneca.

Spotlight on Major New Studies

June brings several high-profile new trials to Seattle, including significant Phase 3 studies from major sponsors. These offer participants the chance to engage with cutting-edge treatments and diagnostic approaches:

• Novo Nordisk A/S is sponsoring NCT07627074, "Weight Loss in Adults Using Semaglutide (Real-world Study)." This large-scale observational study aims for 35,000 participants to assess weight loss in individuals treated with commercially available semaglutide in routine clinical practice.
• Kallyope Inc. is initiating a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial seeks 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo for acute migraine treatment.
• AstraZeneca is leading NCT07662213, a Phase 3 study titled "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This trial aims for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron against oral semaglutide in adults with Type 2 Diabetes Mellitus and increased cardiovascular risk.
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term observational study seeks 1,400 participants of all ages with Down syndrome to better understand their health, development, and everyday experiences.
• Visby Medical is conducting NCT07659808, "Clinical Evaluation of Visby Medical Men's Sexual Health Test." This multi-center study involves 1,000 participants and evaluates the performance of a sexual health test run by male subjects on self-collected urine samples.
• The University of British Columbia is sponsoring NCT07629154, "Smart Discharges for Older Children." This observational multi-country cohort study aims for 4,000 participants to build algorithms identifying children at risk of mortality after discharge for sepsis in East Africa.

Seattle's Leading Research Hubs

Seattle is home to several prominent research institutions that consistently lead in the volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Washington (182 trials)
• Seattle Children's Hospital (169 trials)
• Fred Hutchinson Cancer Center (138 trials)
• Fred Hutch/University of Washington Cancer Consortium (81 trials)
• Swedish Medical Center-First Hill (72 trials)
• University of Washington Medical Center (48 trials)
• Swedish Cancer Institute (46 trials)
• Swedish Medical Center-Cherry Hill (43 trials)
• Swedish Medical Center (43 trials)
• Swedish Medical Center-Ballard Campus (43 trials)
• University of Washington Medical Center - Montlake (43 trials)
• Virginia Mason Medical Center (39 trials)

These institutions, including the University of Washington's various campuses, Seattle Children's Hospital, Fred Hutchinson Cancer Center, and the Swedish Medical Center network, collectively offer a broad spectrum of research, from oncology and pediatric care to general medicine and specialized treatments.

Expanding Your Search: Options Beyond Seattle

While Seattle offers a vast array of clinical trial opportunities, residents of Washington State may also find options in nearby communities. Cities with active trials include Renton (9 trials), Bellevue (2 trials), Kirkland (1 trial), Redmond (1 trial), Spokane (1 trial), Tacoma (1 trial), and Vancouver (1 trial). Exploring these nearby locations can broaden the scope of available studies.

Who Can Participate? Diverse Opportunities

Clinical trials in Seattle are open to a diverse range of individuals. Of the 22 new trials launched this month, 6 include children and 20 include older adults, ensuring that various age groups have opportunities to contribute. One new trial is male-only, with no female-only trials opening this month. For individuals without a specific medical condition, there are significant opportunities to contribute to research; 2 of the new trials accept healthy volunteers, adding to the total of 116 trials currently recruiting healthy participants in Seattle.

As June progresses, Seattle's vibrant research community continues to drive medical innovation, offering diverse and impactful opportunities for individuals to contribute to the future of healthcare.